Hospital-acquired PneumoniaNCT03361085
Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)
A study testing nvHAP Prevention Bundle in people with Hospital-acquired Pneumonia and Healthcare Associated Infection, run by University of Zurich at 1 site in Switzerland.
Trial summary
Background: Hospital acquired pneumonia (HAP) is divided in two distinct groups, ventilator-associated pneumonia (VAP) and non-ventilator-associated HAP (nvHAP). Although nvHAP occurs more frequently than VAP and results in similar mortality and costs, prevention guidelines and prevention focus almost exclusively on… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hospital-acquired Pneumonia, Healthcare Associated Infection, Infection Prevention
- What is being tested?
- nvHAP Prevention Bundle
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45,000 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jan 2018to 28 Feb 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
The study population consists of all patients hospitalized in nine predefined medical and surgical departments and their corresponding wards chosen based on the following criteria
- nvHAP rate above the 50th percentile according to UHZ nvHAP data from the year 2017
- high absolute number of patients with nvHAP according to UHZ nvHAP data from the year 2017
- organizational structure, e.g. departments sharing same nursing or medical personnel
- representing both medical and surgical specialties.
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Zurich, Dept. of Infectious Diseases and Hospital Epidemiology
Zurich, Canton of Zurich, 8091
About this study
Background: Hospital acquired pneumonia (HAP) is divided in two distinct groups, ventilator-associated pneumonia (VAP) and non-ventilator-associated HAP (nvHAP). Although nvHAP occurs more frequently than VAP and results in similar mortality and costs, prevention guidelines and prevention focus almost exclusively on VAP. Scientific evidence about nvHAP prevention is scarce. Therefore, we designed a mixed-methods study to investigate the effectiveness of a newly developed nvHAP prevention bundle and factors that influence its implementation.
Methods: This single-centre project at the 950-bed University Hospital Zurich (UHZ) will engage the wards of nine departments with substantial nvHAP rates. The nvHAP bundle consists of five primary prevention measures: 1) oral care, 2) identification and treatment of patients with dysphagia, 3) mobilization, 4) stopping unnecessary proton pump inhibitors, and, 5) respiratory therapy. Implementation includes the engagement of department-level implementation teams, who sustain the 'core' intervention components of education, training, and environmental restructuring and adapt the implementation strategy to local needs. The effects of the implementation will be analysed by a mixed-method approach. As primary outcome, nvHAP incidence rates will be analysed by Poisson regression models to compare incidence rates before, during, and after the implementation phases (on the hospital and department level). In addition, the association between process indicators and nvHAP incidence rates will be analysed using longitudinal Poisson regression models. A longitudinal, qualitative study and formative evaluation based on interviews and focus groups identifies supporting or hindering factors for implementation success in participating departments dynamically over time. This accumulating implementation experience will be constantly fed back to the implementation teams and thus, represents an active implementation element.
Discussion: This comprehensive mixed-methods study is designed to accomplish both, measure the effectiveness of a new prevention bundle against nvHAP and provide insights into how and why it worked or failed. The results of this study may contribute substantially to patient safety in the area of a rediscovered healthcare-associated infection - nvHAP.
Read the detailed description
Methods
Aim:
With this mixed-methods study, we aim to investigate the impact of the implementation of a newly designed nvHAP prevention bundle on the nvHAP incidence rate among inpatients in our tertiary care hospital. We will quantify the adherence to the individual bundle elements and qualitatively identify the factors that influence successful implementation.
Objectives:
- To determine the nvHAP bundle effectiveness on the nvHAP incidence rate
- To determine the adherence the nvHAP bundle and each of the bundle elements
- To relate adherence to nvHAP bundle elements with nvHAP incidence rate
- To qualitatively monitor changes and identify trends in implementation outcomes throughout the study periods
- To identify which factors in the implementation setting are associated with the actual degree of local implementation of the nvHAP bundle
Study setting:
The study is conducted at the University Hospital Zurich (UHZ), Switzerland, a 950-bed tertiary-care teaching hospital covering all medical specialties except paediatrics and orthopaedics.
Study population:
The study population consists of all patients hospitalized in nine predefined medical and surgical departments and their corresponding wards chosen based on the following criteria; 1) nvHAP rate above the 50th percentile according to UHZ nvHAP data from the year 2017; 2) high absolute number of patients with nvHAP according to UHZ nvHAP data from the year 2017; 3) organizational structure, e.g. departments sharing same nursing or medical personnel; 4) representing both medical and surgical specialties.
Intervention:
The nvHAP bundle: The University Hospital Zurich nvHAP bundle was designed by an interprofessional and interdisciplinary group of experts. Elements were chosen based on the evidence, although scarce, of their effectiveness and based on their anticipated feasibility and implementability. The bundle consists of five prevention measures (details see Annex nvHAP Bundle).
- Oral care, i.e. mechanical and pharmacological oral care
- Identification and treatment of patients with dysphagia, i.e. by applying a 'modified swallowing assessment' (MSA) adapted from the 'Standardized Swallowing Assessment' by Perry et al. (15) (Annex 'MSA Perry')
- Mobilization, i.e. mobilization at least twice daily
- Stopping unnecessary PPI and antacids
- Respiratory therapy As not all bundle elements apply to all patients, the patients will first be assessed for indication of the respective prevention measure after admission, clinical deterioration, and major surgery during hospital stay. The execution of the bundle element has to be documented in the electronic medical record (EMR).
Implementation strategy and formative evaluation: Our implementation strategy is designed to increase ownership and local adoption in each department by engaging local implementation teams, who establish department-specific actions based on local needs. This strategy is also intended to facilitate adaptability, i.e. the degree to which the intervention can be adapted to meet local needs (16, 17). Based on an initial behavioural analysis informed by sensitizing frameworks (see below, "Implementation Frameworks") (16, 18, 19), we identified the following as promising intervention functions to increase adherence to the nvHAP bundle: increasing knowledge and understanding about the nvHAP bundle elements through education; imparting skills through technical training; and changing the physical context to increase awareness and support performance of nvHAP measures through environmental restructuring. Whereas these intervention functions to increase adherence to the nvHAP bundle elements make up the foreseeable core intervention components, each department is encouraged to adapt the delivery of these components and to employ additional promotional components according to local context, making up the 'soft periphery' of the intervention.
Local implementation teams, composed of one nurse, one physician and one physiotherapist, will be established in each department. During recurrent "action plan" meetings, the local implementation team from each department, with support from the nvHAP study team, will be responsible for assessing the current implementation status with respect to each bundle element and establishing an "action plan" with a list of planned actions aimed to increase adherence to bundle elements according to local needs. Local implementation teams will be responsible for implementing the nvHAP bundle in their respective departments. Established "action plans" will be revisited to assess progress and refine necessary actions, as described below.
The nvHAP study team, based in the infection prevention department, will form a central coordinating team to provide local teams with support, example training materials, and feedback on process and outcome data. Additionally, we will employ a formative approach, during which we aim to continuously identify influences on implementation efforts (e.g. barriers and facilitators) and feed these insights back to local implementation teams to optimize the potential for implementation success (20). This formative evaluation will occur in stages throughout the project, as described by Stetler and colleagues (20) and presented in Table 1. The formative evaluation will rely primarily on "action plan" meetings as an opportunity to feed information back to local implementation teams regarding identified barriers and facilitators to implementation and to refine implementation action plans accordingly.
Study design:
This mixed methods study collects and analyses quantitative and qualitative data collected during the three study periods (baseline, implementation, and intervention period).
Study periods:
Baseline period will start at the same time for all departments and will be of different length (minimum 12 months) as implementation of nvHAP prevention measures will occur at the department level and the start of implementation activities is chosen by every department, primarily relying on availability of resources.
We define three study periods on the department level, 1) department baseline period, before implementation of nvHAP bundle in the specific department; 2) department implementation period, a two month time frame starting with the beginning of implementation activities in the respective department; 3) department intervention period following the department implementation period.
On the hospital level the three periods are defined as follows: 1) hospital baseline period, before starting implementation in the first department; 2) hospital implementation period, from the beginning of the implementation period of the first department until end of implementation period of the last included department; 3) hospital intervention period following the hospital implementation period.
Implementation framework:
Our study is theoretically informed by the Consolidated Framework for Implementation Research (CFIR) (16) and the Theoretical Domains Framework (TDF). Both the CFIR and the TDF integrate findings from theoretical literature into synthesized frameworks consisting of constructs that may mediate behaviour change. Whereas the TDF domains represent a set of constructs related to individual behaviour change, the CFIR domains include constructs relating to broader organizational behaviour change. For the current inquiry, we find the use of both frameworks useful to capture influencers of behaviour at the individual level, as well as the department, the overall hospital, and the wider environmental context. The CFIR and the TDF will inform the intervention implementation strategy, as previously described, and guide the qualitative data collection (semi-structured interview guides) and analyses (use of TDF as deductive coding framework). In particular, use of these sensitising frameworks throughout our study will facilitate the timely identification of barriers and facilitators and will also provide insights as to which additional intervention components are most likely to be successful in addressing the identified barriers.
Data collection:
Data sources: In the study hospital, all patient data are charted electronically via an EMR system. Selected data are stored in a clinical data warehouse.
NvHAP surveillance We apply the European Centre for Disease Prevention and Control (ECDC) definition criteria for pneumonia that are used in the ECDC point prevalence studies (10) (Annex 'ECDC Definition nvHAP') and a validated semi-automated surveillance system for nvHAP is used (22). Place of nvHAP acquisition is defined as department, ward and room to which the patient was affiliated 48h before first symptoms of nvHAP, unless shorter incubation period was evident from patient history.
Process indicators:
Process indicators portraying adherence to the nvHAP bundle elements will be monitored in two ways. First, for all five prevention measures, at least one surrogate parameter for adherence is continuously extracted from the EMR of the total patient population (continuous process indicators; see Annex 'Process indicators'). This parameter, e.g. toothbrushing provided by nurses, will be expressed per department, and month, and either hospital days or admissions. Second, we will monitor process indicators on a sample basis with individual assessment of a subset of patients at four different time points per department (intermittent process indicators; see Annex 'Process indicators'). The latter allows a more detailed description of adherence, including non-documented prevention measures (e.g. oral care executed by patient) and takes into consideration the individual need of patients for the specific prevention measure (e.g. respiratory therapy is indicated only in a subset of patients). From the intermittent process indicators the 'nvHAP adherence score' will assess patient based adherence per department and time point. The score is based on samples of 50 patients, the 'nvHAP adherence indicator' takes the value 1 in the case the specific prevention measure was completed in the specific patient, 0 if that was not the case, and "empty" in the case of missing values. The 'nvHAP adherence score' is calculated by summing up the five proportions of patients with completed specific prevention measures (i.e. 'nvHAP adherence indicator'=1) dividing it by factor five (Annex 'nvHAP adherence score').
Qualitative data collection:
Longitudinal qualitative data will be collected throughout the project as portrayed in Figure 2, including action plan interviews with local implementation teams, drop-in interviews with frontline staff, and focus group interviews, as described in Table 2. These three data collection activities will allow for rigorous triangulation of findings among data sources and will all inform the ongoing formative evaluation (see Table 1).
- Being tested
- nvHAP Prevention Bundle
- Keywords
- non-ventilator-associated hospital acquired pneumonia, Hospital-acquired Pneumonia, Healthcare Associated Infection, Adherence, infection prevention, implementation
- Medical subject headings
- Healthcare-Associated Pneumonia, Cross Infection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
nvHAP Prevention BundleProcedure or surgery
oral care, (early) mobilization, diagnosis and treatment of dysphagia, respiratory physiotherapy, stop Proton pump Inhibitors (PPI) if reasonable
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | nvHAP-Prevention Bundle Receives: Procedure: nvHAP Prevention Bundle |
What is being measured
The primary outcome is the main question the study is designed to answer.
nvHAP Incidence rate
non Ventilator-associated Hospital acquired Pneumonia according to ECDC definitions
Measured: up to 3 months post-discharge
Secondary outcomes (2)
Percentage of patients who passed away during hospitalization (in-hospital mortality)
death during hospitalisation
Measured: up to 3 months post-discharge
length of stay
Duration of hospitalisation
Measured: up to 3 months post-discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2017
- Study start1 Jan 2018
- Primary completion28 Feb 2020
- Study completion28 Feb 2020
Why it stopped: COVID-Epidemic with changes in patient mix, restructuring of wards/departments, new standard-precautions
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Hospital-acquired PneumoniaStudies of the same condition, open and under way.
- More trials run by University of ZurichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Intervention model
- Sequential
- Model description
- quasi experimental intervention study
- Masking
- None (open label)
- Enrolment
- 45,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Aline Wolfensberger, MD, Principal investigator, University of ZurichLauren Clack, PhD, Principal investigator, University of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03361085
- Sponsor's protocol ID
- UHZ nvHAP Bundle
- Status last verified
- Jul 2020
- First submitted
- 30 Oct 2017
- Last updated
- 14 Jul 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Wolfensberger A, Clack L, von Felten S, Faes Hesse M, Saleschus D, Meier MT, Kusejko K, Kouyos R, Held L, Sax H. Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness-implementation trial. Lancet Infect Dis. 2023 Jul;23(7):836-846. doi: 10.1016/S1473-3099(22)00812-X. Epub 2023 Mar 6.
PubMed 36893785Wolfensberger A, Clack L, von Felten S, Kusejko K, Faes Hesse M, Jakob W, Saleschus D, Meier MT, Kouyos R, Held L, Sax H. Implementation and evaluation of a care bundle for prevention of non-ventilator-associated hospital-acquired pneumonia (nvHAP) - a mixed-methods study protocol for a hybrid type 2 effectiveness-implementation trial. BMC Infect Dis. 2020 Aug 17;20(1):603. doi: 10.1186/s12879-020-05271-5.
PubMed 32807090
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)
- ClinicalTrials.gov ID
- NCT03361085
- Acronym / sponsor ID
- UHZ nvHAP Bundle
- Keywords
- non-ventilator-associated hospital acquired pneumonia, Hospital-acquired Pneumonia, Healthcare Associated Infection, Adherence, infection prevention, implementation
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: COVID-Epidemic with changes in patient mix, restructuring of wards/departments, new standard-precautions
- Enrolment
- 45,000 participants (actual)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 28 Feb 2020 (actual)
- Study completion
- 28 Feb 2020 (actual)
- First posted
- 4 Dec 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Hospital acquired pneumonia (HAP) is divided in two distinct groups, ventilator-associated pneumonia (VAP) and non-ventilator-associated HAP (nvHAP). Although nvHAP occurs more frequently than VAP and results in similar mortality and costs, prevention guidelines and prevention focus almost exclusively on VAP. Scientific evidence about nvHAP prevention is scarce. Therefore, we designed a mixed-methods study to investigate the effectiveness of a newly developed nvHAP prevention bundle and factors that influence its implementation.
Methods: This single-centre project at the 950-bed University Hospital Zurich (UHZ) will engage the wards of nine departments with substantial nvHAP rates. The nvHAP bundle consists of five primary prevention measures: 1) oral care, 2) identification and treatment of patients with dysphagia, 3) mobilization, 4) stopping unnecessary proton pump inhibitors, and, 5) respiratory therapy. Implementation includes the engagement of department-level implementation teams, who sustain the 'core' intervention components of education, training, and environmental restructuring and adapt the implementation strategy to local needs. The effects of the implementation will be analysed by a mixed-method approach. As primary outcome, nvHAP incidence rates will be analysed by Poisson regression models to compare incidence rates before, during, and after the implementation phases (on the hospital and department level). In addition, the association between process indicators and nvHAP incidence rates will be analysed using longitudinal Poisson regression models. A longitudinal, qualitative study and formative evaluation based on interviews and focus groups identifies supporting or hindering factors for implementation success in participating departments dynamically over time. This accumulating implementation experience will be constantly fed back to the implementation teams and thus, represents an active implementation element.
Discussion: This comprehensive mixed-methods study is designed to accomplish both, measure the effectiveness of a new prevention bundle against nvHAP and provide insights into how and why it worked or failed. The results of this study may contribute substantially to patient safety in the area of a rediscovered healthcare-associated infection - nvHAP.
Detailed description
Methods
Aim:
With this mixed-methods study, we aim to investigate the impact of the implementation of a newly designed nvHAP prevention bundle on the nvHAP incidence rate among inpatients in our tertiary care hospital. We will quantify the adherence to the individual bundle elements and qualitatively identify the factors that influence successful implementation.
Objectives:
- To determine the nvHAP bundle effectiveness on the nvHAP incidence rate
- To determine the adherence the nvHAP bundle and each of the bundle elements
- To relate adherence to nvHAP bundle elements with nvHAP incidence rate
- To qualitatively monitor changes and identify trends in implementation outcomes throughout the study periods
- To identify which factors in the implementation setting are associated with the actual degree of local implementation of the nvHAP bundle
Study setting:
The study is conducted at the University Hospital Zurich (UHZ), Switzerland, a 950-bed tertiary-care teaching hospital covering all medical specialties except paediatrics and orthopaedics.
Study population:
The study population consists of all patients hospitalized in nine predefined medical and surgical departments and their corresponding wards chosen based on the following criteria; 1) nvHAP rate above the 50th percentile according to UHZ nvHAP data from the year 2017; 2) high absolute number of patients with nvHAP according to UHZ nvHAP data from the year 2017; 3) organizational structure, e.g. departments sharing same nursing or medical personnel; 4) representing both medical and surgical specialties.
Intervention:
The nvHAP bundle: The University Hospital Zurich nvHAP bundle was designed by an interprofessional and interdisciplinary group of experts. Elements were chosen based on the evidence, although scarce, of their effectiveness and based on their anticipated feasibility and implementability. The bundle consists of five prevention measures (details see Annex nvHAP Bundle).
- Oral care, i.e. mechanical and pharmacological oral care
- Identification and treatment of patients with dysphagia, i.e. by applying a 'modified swallowing assessment' (MSA) adapted from the 'Standardized Swallowing Assessment' by Perry et al. (15) (Annex 'MSA Perry')
- Mobilization, i.e. mobilization at least twice daily
- Stopping unnecessary PPI and antacids
- Respiratory therapy As not all bundle elements apply to all patients, the patients will first be assessed for indication of the respective prevention measure after admission, clinical deterioration, and major surgery during hospital stay. The execution of the bundle element has to be documented in the electronic medical record (EMR).
Implementation strategy and formative evaluation: Our implementation strategy is designed to increase ownership and local adoption in each department by engaging local implementation teams, who establish department-specific actions based on local needs. This strategy is also intended to facilitate adaptability, i.e. the degree to which the intervention can be adapted to meet local needs (16, 17). Based on an initial behavioural analysis informed by sensitizing frameworks (see below, "Implementation Frameworks") (16, 18, 19), we identified the following as promising intervention functions to increase adherence to the nvHAP bundle: increasing knowledge and understanding about the nvHAP bundle elements through education; imparting skills through technical training; and changing the physical context to increase awareness and support performance of nvHAP measures through environmental restructuring. Whereas these intervention functions to increase adherence to the nvHAP bundle elements make up the foreseeable core intervention components, each department is encouraged to adapt the delivery of these components and to employ additional promotional components according to local context, making up the 'soft periphery' of the intervention.
Local implementation teams, composed of one nurse, one physician and one physiotherapist, will be established in each department. During recurrent "action plan" meetings, the local implementation team from each department, with support from the nvHAP study team, will be responsible for assessing the current implementation status with respect to each bundle element and establishing an "action plan" with a list of planned actions aimed to increase adherence to bundle elements according to local needs. Local implementation teams will be responsible for implementing the nvHAP bundle in their respective departments. Established "action plans" will be revisited to assess progress and refine necessary actions, as described below.
The nvHAP study team, based in the infection prevention department, will form a central coordinating team to provide local teams with support, example training materials, and feedback on process and outcome data. Additionally, we will employ a formative approach, during which we aim to continuously identify influences on implementation efforts (e.g. barriers and facilitators) and feed these insights back to local implementation teams to optimize the potential for implementation success (20). This formative evaluation will occur in stages throughout the project, as described by Stetler and colleagues (20) and presented in Table 1. The formative evaluation will rely primarily on "action plan" meetings as an opportunity to feed information back to local implementation teams regarding identified barriers and facilitators to implementation and to refine implementation action plans accordingly.
Study design:
This mixed methods study collects and analyses quantitative and qualitative data collected during the three study periods (baseline, implementation, and intervention period).
Study periods:
Baseline period will start at the same time for all departments and will be of different length (minimum 12 months) as implementation of nvHAP prevention measures will occur at the department level and the start of implementation activities is chosen by every department, primarily relying on availability of resources.
We define three study periods on the department level, 1) department baseline period, before implementation of nvHAP bundle in the specific department; 2) department implementation period, a two month time frame starting with the beginning of implementation activities in the respective department; 3) department intervention period following the department implementation period.
On the hospital level the three periods are defined as follows: 1) hospital baseline period, before starting implementation in the first department; 2) hospital implementation period, from the beginning of the implementation period of the first department until end of implementation period of the last included department; 3) hospital intervention period following the hospital implementation period.
Implementation framework:
Our study is theoretically informed by the Consolidated Framework for Implementation Research (CFIR) (16) and the Theoretical Domains Framework (TDF). Both the CFIR and the TDF integrate findings from theoretical literature into synthesized frameworks consisting of constructs that may mediate behaviour change. Whereas the TDF domains represent a set of constructs related to individual behaviour change, the CFIR domains include constructs relating to broader organizational behaviour change. For the current inquiry, we find the use of both frameworks useful to capture influencers of behaviour at the individual level, as well as the department, the overall hospital, and the wider environmental context. The CFIR and the TDF will inform the intervention implementation strategy, as previously described, and guide the qualitative data collection (semi-structured interview guides) and analyses (use of TDF as deductive coding framework). In particular, use of these sensitising frameworks throughout our study will facilitate the timely identification of barriers and facilitators and will also provide insights as to which additional intervention components are most likely to be successful in addressing the identified barriers.
Data collection:
Data sources: In the study hospital, all patient data are charted electronically via an EMR system. Selected data are stored in a clinical data warehouse.
NvHAP surveillance We apply the European Centre for Disease Prevention and Control (ECDC) definition criteria for pneumonia that are used in the ECDC point prevalence studies (10) (Annex 'ECDC Definition nvHAP') and a validated semi-automated surveillance system for nvHAP is used (22). Place of nvHAP acquisition is defined as department, ward and room to which the patient was affiliated 48h before first symptoms of nvHAP, unless shorter incubation period was evident from patient history.
Process indicators:
Process indicators portraying adherence to the nvHAP bundle elements will be monitored in two ways. First, for all five prevention measures, at least one surrogate parameter for adherence is continuously extracted from the EMR of the total patient population (continuous process indicators; see Annex 'Process indicators'). This parameter, e.g. toothbrushing provided by nurses, will be expressed per department, and month, and either hospital days or admissions. Second, we will monitor process indicators on a sample basis with individual assessment of a subset of patients at four different time points per department (intermittent process indicators; see Annex 'Process indicators'). The latter allows a more detailed description of adherence, including non-documented prevention measures (e.g. oral care executed by patient) and takes into consideration the individual need of patients for the specific prevention measure (e.g. respiratory therapy is indicated only in a subset of patients). From the intermittent process indicators the 'nvHAP adherence score' will assess patient based adherence per department and time point. The score is based on samples of 50 patients, the 'nvHAP adherence indicator' takes the value 1 in the case the specific prevention measure was completed in the specific patient, 0 if that was not the case, and "empty" in the case of missing values. The 'nvHAP adherence score' is calculated by summing up the five proportions of patients with completed specific prevention measures (i.e. 'nvHAP adherence indicator'=1) dividing it by factor five (Annex 'nvHAP adherence score').
Qualitative data collection:
Longitudinal qualitative data will be collected throughout the project as portrayed in Figure 2, including action plan interviews with local implementation teams, drop-in interviews with frontline staff, and focus group interviews, as described in Table 2. These three data collection activities will allow for rigorous triangulation of findings among data sources and will all inform the ongoing formative evaluation (see Table 1).
Study design
- Primary purpose
- Prevention
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- quasi experimental intervention study
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Procedure: nvHAP Prevention BundlenvHAP-Prevention Bundle |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| nvHAP Prevention Bundleoral care, (early) mobilization, diagnosis and treatment of dysphagia, respiratory physiotherapy, stop Proton pump Inhibitors (PPI) if reasonable | Procedure or surgery | Intervention |
Primary outcome
nvHAP Incidence rate
Time frame: up to 3 months post-discharge
non Ventilator-associated Hospital acquired Pneumonia according to ECDC definitions
2 secondary outcomes
Percentage of patients who passed away during hospitalization (in-hospital mortality)
Time frame: up to 3 months post-discharge
length of stay
Time frame: up to 3 months post-discharge
Results and safety
The study was stopped early (reason given: COVID-Epidemic with changes in patient mix, restructuring of wards/departments, new standard-precautions). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2020.
- Derived from this study: PubMed 36893785Wolfensberger A, Clack L, von Felten S, Faes Hesse M, Saleschus D, Meier MT, Kusejko K, Kouyos R, Held L, Sax H. Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness-implementation trial. Lancet Infect Dis. 2023 Jul;23(7):836-846. doi: 10.1016/S1473-3099(22)00812-X. Epub 2023 Mar 6.
- Derived from this study: PubMed 32807090Wolfensberger A, Clack L, von Felten S, Kusejko K, Faes Hesse M, Jakob W, Saleschus D, Meier MT, Kouyos R, Held L, Sax H. Implementation and evaluation of a care bundle for prevention of non-ventilator-associated hospital-acquired pneumonia (nvHAP) - a mixed-methods study protocol for a hybrid type 2 effectiveness-implementation trial. BMC Infect Dis. 2020 Aug 17;20(1):603. doi: 10.1186/s12879-020-05271-5.
- Individual participant dataSharing planned: No
Related trials for Hospital-acquired Pneumonia
Not yet recruitingObservational study
Traditional Chinese Medicine in Multidrug-Resistant Bacterial Pneumonia
Multi Drug Resistant Infections, Pneumnia
RecruitingPhase 4
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Blood Stream Infections, Ventilator Associated Pneumonia
Not yet recruitingPhase 3
Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP)
Active, not recruiting
HAP/VAP Diagnosis in Critically Ill Septic Patients Using a Multiplex PCR Array
HAP - Hospital Acquired Pneumonia, VAP - Ventilator Associated Pneumonia
RecruitingPhase 1
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Aline Wolfensberger, MD principal investigator
University of Zurich
Lauren Clack, PhD principal investigator
University of Zurich
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing nvHAP Prevention Bundle in people with Hospital-acquired Pneumonia and Healthcare Associated Infection, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 14 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: COVID-Epidemic with changes in patient mix, restructuring of wards/departments, new standard-precautions). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
nvHAP Incidence rate (time frame: up to 3 months post-discharge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03361085, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2020.